Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

igen. "We continue to expect we will receive the analysis from the DMC and complete our review by early December."

"We expect that an interim analysis that meets the pre-specified safety hurdles will enable a series of important steps in 2014 toward the global commercialization of Contrave, including potential approvals in the US and Europe, progression of partnership discussions for ex-North American Contrave rights, and the potential commercial launch of Contrave in North America by Takeda," Narachi continued.

Recent business highlights:

  • In October, Orexigen submitted the Marketing Authorization Application for Contrave to the European Medicines Agency. Cardiovascular outcomes data from the Light Study are expected to be available for the Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions.
  • In preparation for the potential launch of Contrave, Takeda assumed from the Company the responsibility to package Contrave for commercial sale. The Company will continue to supply bulk tablets of Contrave to Takeda in accordance with the terms of the Collaboration Agreement.
  • Orexigen entered into a commercial supply agreement with Sanofi to manufacture and supply Contrave for territories outside North America.
  • Product candidates: Contrave (32 mg naltrexone sustained‐release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double‐blind, randomized, placebo‐controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA (United States Food and Drug Administration), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis of the Light Study is anticipated by early Decem
    '/>"/>

    SOURCE Orexigen Therapeutics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
    2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
    3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
    4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
    5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
    6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
    7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
    8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
    9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
    10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
    11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... -- About Chronic Lymphocytic Leukemia Chronic ... production of lymphocytes. It has been observed that the ... to other parts of the body. This leukemia is ... buildup of the cancerous cells. During the course of ... and lymph nodes. The course of the disease is ...
    (Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/275q7t/inhaled_drug ) ... Delivery (London, UK - November 19-20, 2015)" conference ... meeting will cover industry case studies, regulatory updates, latest ... are Dr Steven Nichols , OINP Specialist Consultant ... Companies participating include: - ...
    (Date:9/2/2015)... Sept. 2, 2015 Research and Markets ... the "An Introduction to Medical Device Software: ... 2015)" conference to their offering. ... to the regulations and requirements that apply to ... interactive, using real life examples and state-of- the-art ...
    Breaking Medicine Technology:Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 2Global Chronic Lymphocytic Leukemia Therapeutics Market 2015-2019 3An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
    (Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
    (Date:9/2/2015)... ... September 02, 2015 , ... Specifically, ... the news recently following a decision by the Centers for Medicare & Medicaid ... to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. ...
    (Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an ... of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone ... usability. A leader in health technology, RxNT was one of the first to ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
    (Date:9/2/2015)... ... 2015 , ... A UPMC and University of Pittsburgh Schools ... a premier center for treatment of and research into hereditary hemorrhagic telangiectasia (HHT), ... , Cure HHT, previously known as The HHT Foundation International, has designated ...
    Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
    ... BEIJING, June 26 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin ... China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"),has obtained ... that aid in manufacturing blood dialysis. , ... for patents for its core,technology with the State Intellectual ...
    ... HOUSTON, June 26 The Breast Center at Houston Northwest ... the United States -- and one in Texas -- to ... by the National Quality Measures for Breast Centers (NQMBC) Program(TM). ... measure performance of interdisciplinary breast care nationwide. The designation is ...
    ... ... in Omaha list for the second straight year. The list is sponsored by the Greater Omaha ... an Omaha business. , ... June 26, 2009 -- Healthcare staffing company Medical Solutions has landed on the ...
    ... DC (26 June, 2009) Combating high blood pressure ... enjoyed reductions in cardiovascular disease over recent decades, Latin ... published in the journal Therapeutic Advances in Cardiovascular ... the increase in many Latin American countries, a situation ...
    ... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... the Food and Drug Administration, today arrived and seized ... also included ingredients held at these same facilities. The ... in May 2009, found unresolved violations of cGMP requirements ...
    ... Texas, June 25 Torchmark Corporation (NYSE: TMK ... $300 million in aggregate principal amount of 9.25% Senior Notes ... to close on June 30, 2009, subject to the satisfaction ... offering will be used for the repayment of the $99.45 ...
    Cached Medicine News:Health News:RainEarth Obtains Patent Approvals for Its Core Technology 2Health News:RainEarth Obtains Patent Approvals for Its Core Technology 3Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 2Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4Health News:Latin America must cut blood pressure to thrive 2Health News:Latin America must cut blood pressure to thrive 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action 2Health News:Torchmark Prices Senior Notes Offering 2
    AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
    Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
    Medicine Products: